PURPOSE: Free plasma RNA has been scarcely studied in patients with cancer. Here we examine the presence of RNA from epithelial tumors in plasma from a series of breast cancer patients and its correlation with tumor characteristics and circulating tumor cells. EXPERIMENTAL DESIGN: beta-actin mRNA was analyzed to check the viability of plasma RNA in samples from 45 patients with breast cancer and 25 controls. Nested primers were used to detect the presence of cytokeratin 19 (CK19) and Mammaglobin in the same samples. Eleven clinicopathological parameters were studied and correlated with molecular parameters. Additionally, we looked for circulating tumor cells in 16 of these patients and in 10 of the controls. RESULTS: All samples showed detectable quantities of beta-actin RNA. In controls, 3 cases (12%) were positive for Mammaglobin, and 5 (20%) were positive for CK19 RNA; of the 45 patients, 27 cases (60%) were positive for Mammaglobin, and 22 (49%) were positive for CK19. These differences were statistically significant (P = 0.001). Tumor size (P = 0.01) and proliferative index (P = 0.02) were associated with the presence of Mammaglobin, CK19, or both RNAs in plasma. Pathological stage (P = 0.06) was close to significance. Although a statistical relationship was not demonstrated, 9 of the 10 patients with circulating tumor cells showed epithelial mRNAs in plasma. CONCLUSIONS: We conclude that epithelial tumor RNA is detectable in plasma from breast cancer patients and that this finding is associated with a probable poor prognosis and circulating tumor cells.
PURPOSE: Free plasma RNA has been scarcely studied in patients with cancer. Here we examine the presence of RNA from epithelial tumors in plasma from a series of breast cancerpatients and its correlation with tumor characteristics and circulating tumor cells. EXPERIMENTAL DESIGN:beta-actin mRNA was analyzed to check the viability of plasma RNA in samples from 45 patients with breast cancer and 25 controls. Nested primers were used to detect the presence of cytokeratin 19 (CK19) and Mammaglobin in the same samples. Eleven clinicopathological parameters were studied and correlated with molecular parameters. Additionally, we looked for circulating tumor cells in 16 of these patients and in 10 of the controls. RESULTS: All samples showed detectable quantities of beta-actin RNA. In controls, 3 cases (12%) were positive for Mammaglobin, and 5 (20%) were positive for CK19 RNA; of the 45 patients, 27 cases (60%) were positive for Mammaglobin, and 22 (49%) were positive for CK19. These differences were statistically significant (P = 0.001). Tumor size (P = 0.01) and proliferative index (P = 0.02) were associated with the presence of Mammaglobin, CK19, or both RNAs in plasma. Pathological stage (P = 0.06) was close to significance. Although a statistical relationship was not demonstrated, 9 of the 10 patients with circulating tumor cells showed epithelial mRNAs in plasma. CONCLUSIONS: We conclude that epithelial tumor RNA is detectable in plasma from breast cancerpatients and that this finding is associated with a probable poor prognosis and circulating tumor cells.
Authors: R Ramos-Medina; F Moreno; S Lopez-Tarruella; M Del Monte-Millán; I Márquez-Rodas; E Durán; Y Jerez; J A Garcia-Saenz; I Ocaña; S Andrés; T Massarrah; M González-Rivera; M Martin Journal: Clin Transl Oncol Date: 2015-12-08 Impact factor: 3.405
Authors: Enders K O Ng; Nancy B Y Tsui; Tze K Lau; Tse N Leung; Rossa W K Chiu; Nirmal S Panesar; Lydia C W Lit; Kam-Wing Chan; Y M Dennis Lo Journal: Proc Natl Acad Sci U S A Date: 2003-03-18 Impact factor: 11.205
Authors: Xiao-feng Guan; Mohammad K Hamedani; Adewale Adeyinka; Christina Walker; Angela Kemp; Leigh C Murphy; Peter H Watson; Etienne Leygue Journal: Endocrine Date: 2003-08 Impact factor: 3.633
Authors: José Miguel García; Vanesa García; Cristina Peña; Gemma Domínguez; Javier Silva; Raquel Diaz; Pablo Espinosa; Maria Jesús Citores; Manuel Collado; Félix Bonilla Journal: RNA Date: 2008-05-02 Impact factor: 4.942
Authors: N Mohammed; M Rodriguez; V Garcia; J M Garcia; G Dominguez; C Peña; M Herrera; I Gomez; R Diaz; B Soldevilla; A Herrera; J Silva; F Bonilla Journal: Oncol Lett Date: 2011-04-28 Impact factor: 2.967
Authors: Donald J Johann; Jaime Rodriguez-Canales; Sumana Mukherjee; DaRue A Prieto; Jeffrey C Hanson; Michael Emmert-Buck; Josip Blonder Journal: J Proteome Res Date: 2009-05 Impact factor: 4.466